23 Nov. 2022

Software Developer (SWP Call 2023)

Research
Application Starts: 23 Nov. 2022
Application Ends: 02 Jan. 2023

Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a Software Developer to join our team.

Hands-on course on Zebrafish Xenografts 2023 - 2nd edition

This course is promoted by Champalimaud Foundation's Fior Lab, integrated in the congento - Consortium for Genetically Tractable Organisms - initiatives.

The scientific programme will cover

- Protocols for preparation of human cancer cells for injection;
- Generation of zebrafish xenografts (microinjection in the perivitelline space);
- Metastatic assay;
- Protocols for immunofluorescence;
- Mounting xenografts for confocal imaging;
- Confocal session.

Venue

Champalimaud Center for the Unknown, Lisbon

10 November 2022

Portuguese consortium to receive 78 million euros funding from the Programa de Recuperação e Resiliência to develop “responsible” AI

For every argument that construes AI as essential, promising and transforming across nearly all industries, there are voiced concerns about this technology. Many people do not trust AI, claiming that intelligent machines will one day dominate humankind. But while this is a remote possibility, the harm that can be done to people (albeit mostly unintentionally) by deep learning algorithms is very tangible – and has already been known to occur in the real world.

04 November 2022

Work from Champalimaud Foundation Researcher Acknowledged by the Eppendorf & Science Prize for Neurobiology

After receiving her bachelor's degree in Biochemistry and a master's degree in Health Sciences from the University of Minho, which introduced her to the field of immunology, Cardoso embarked upon a PhD in the laboratory of Henrique Veiga-Fernandes at the Champalimaud Foundation to study the role of neuro-immune interactions in metabolism.

30 Sep. 2022

Two postdoctoral positions - MP 2pd Oct2022

Research
Application Starts: 30 Sep. 2022
Application Ends: 19 Nov. 2022

Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for two Postdoctoral Fellows to join Memming Park’s group (funding from NIH R01 DA056404-04).

Offered conditions

- Competitive remuneration package commensurate with skills, qualifications and experience;
- Full immersion into a research excellence ecosystem with highly motivated researchers, supported by state-of-the-art technology and continuous development opportunities.

27 September 2022

The Champalimaud Foundation will host the Neuro, Digital & AI Innovation Summit

Organised by Broadreach Global with the European Brain Foundation (EBC), this summit will  bring together - in a collaborative, roundtable format - a highly diverse group of key opinion leaders, from  innovators, to decision-makers. 

26 September 2022

Female flies enter the ring of sexual competition

When it comes to sexual competition, males have the star role. Clashing bodies, locking horns, biting and kicking are all considered fair play. Since these behaviours are so salient and robust, most studies focus on male behaviour, leaving females aside. 
 

20 September 2022

Concurso CaixaResearch announces funding awardees: Leopoldo Petreanu among winners

The CaixaResearch Health Research Contest 2022 has selected 33 promising new biomedical and health projects promoted by research centres and universities in Spain and Portugal. Once again affirming that the “la Caixa” Foundation, in collaboration with BPI, supports projects of excellence that can have a positive impact on the health of citizens. 

Within this framework, it has allocated a total of 23.1 million euros to such projects – 20 Spanish and 13 Portuguese – that will be developed over the next three years. 

09 September 2022

Champalimaud Foundation researchers discover new tool for improving pancreatic cancer care

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.
 

18 August 2022

Science Snapshot: (Re) Generating Neurons

To know more about this research:

Digest

Scientific Article

Subscribe to Research Groups
Loading
Please wait...